Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Mammary Gland Biology and Neoplasia
Published in: Journal of Mammary Gland Biology and Neoplasia 1/2017

01-03-2017

A Novel Effect of β-Adrenergic Receptor on Mammary Branching Morphogenesis and its Possible Implications in Breast Cancer

Authors: Lucía Gargiulo, María May, Ezequiel M. Rivero, Sabrina Copsel, Caroline Lamb, John Lydon, Carlos Davio, Claudia Lanari, Isabel A. Lüthy, Ariana Bruzzone

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 1/2017

Login to get access

Abstract

Understanding the mechanisms that govern normal mammary gland development is crucial to the comprehension of breast cancer etiology. β-adrenergic receptors (β-AR) are targets of endogenous catecholamines such as epinephrine that have gained importance in the context of cancer biology. Differences in β2-AR expression levels may be responsible for the effects of epinephrine on tumor vs non-tumorigenic breast cell lines, the latter expressing higher levels of β2-AR. To study regulation of the breast cell phenotype by β2-AR, we over-expressed β2-AR in MCF-7 breast cancer cells and knocked-down the receptor in non-tumorigenic MCF-10A breast cells. In MCF-10A cells having knocked-down β2-AR, epinephrine increased cell proliferation and migration, similar to the response by tumor cells. In contrast, in MCF-7 cells overexpressing the β2-AR, epinephrine decreased cell proliferation and migration and increased adhesion, mimicking the response of the non-tumorigenic MCF-10A cells, thus underscoring that β2-AR expression level is a key player in cell behavior. β-adrenergic stimulation with isoproterenol induced differentiation of breast cells growing in 3-dimension cell culture, and also the branching of murine mammary epithelium in vivo. Branching induced by isoproterenol was abolished in fulvestrant or tamoxifen-treated mice, demonstrating that the effect of β-adrenergic stimulation on branching is dependent on the estrogen receptor (ER). An ER-independent effect of isoproterenol on lumen architecture was nonetheless found. Isoproterenol significantly increased the expression of ERα, Ephrine-B1 and fibroblast growth factors in the mammary glands of mice, and in MCF-10A cells. In a poorly differentiated murine ductal carcinoma, isoproterenol also decreased tumor growth and induced tumor differentiation. This study highlights that catecholamines, through β-AR activation, seem to be involved in mammary gland development, inducing mature duct formation. Additionally, this differentiating effect could be resourceful in a breast tumor context.
Literature
1.
Hovey RC, Trott JF, Vonderhaar BK. Establishing a framework for the functional mammary gland: from endocrinology to morphology. J Mammary Gland Biol Neoplasia. 2002;7(1):17–38.CrossRefPubMed
2.
Zeps N, Bentel JM, Papadimitriou JM, D’Antuono MF, Dawkins HJ. Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth. Differentiation. 1998;62(5):221–6.CrossRefPubMed
3.
Zhang X, Martinez D, Koledova Z, Qiao G, Streuli CH, Lu P. FGF ligands of the postnatal mammary stroma regulate distinct aspects of epithelial morphogenesis. Development. 2014;141(17):3352–62.CrossRefPubMedPubMedCentral
4.
Brisken C, Ataca D. Endocrine hormones and local signals during the development of the mouse mammary gland. Wiley Interdiscip Rev Dev Biol. 2015;4(3):181–95.CrossRefPubMed
5.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
6.
Hasen NS, O’Leary KA, Auger AP, Schuler LA. Social isolation reduces mammary development, tumor incidence, and expression of epigenetic regulators in wild-type and p53-heterozygotic mice. Cancer Prev Res (Phila). 2010;3(5):620–9.CrossRef
7.
Boyd AL, Salleh A, Humber B, Yee J, Tomes L, Kerr LR. Neonatal experiences differentially influence mammary gland morphology, estrogen receptor {alpha} protein levels, and carcinogenesis in BALB/c mice. Cancer Prev Res (Phila). 2010;3(11):1398–408.CrossRef
8.
Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18(5):1201–6.CrossRefPubMed
9.
Tang J, Li Z, Lu L, Cho CH. Beta-adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 2013;23(6 Pt B):533–42.CrossRefPubMed
10.
Perez PC, Bruzzone A, Sarappa M, Castillo L, Luthy I. Involvement of alpha2- and beta2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol. 2012;166(2):721–36.CrossRef
11.
Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C, Seidler FJ. Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer ResTreat. 2000;60(2):153–66.CrossRef
12.
Carie AE, Sebti SM. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 2007;26(26):3777–88.CrossRefPubMed
13.
Inderwies T, Pfaffl MW, Meyer HH, Blum JW, Bruckmaier RM. Detection and quantification of mRNA expression of alpha- and beta-adrenergic receptor subtypes in the mammary gland of dairy cows. Domest Anim Endocrinol. 2003;24(2):123–35.CrossRefPubMed
14.
Marchetti B, Fortier MA, Poyet P, Follea N, Pelletier G, Labrie F. Beta-adrenergic receptors in the rat mammary gland during pregnancy and lactation: characterization, distribution, and coupling to adenylate cyclase. Endocrinology. 1990;126(1):565–74.CrossRefPubMed
15.
Wellner RB, He XJ, Marmary Y, Baum BJ. Functional beta-adrenergic receptors in a human mammary cell line (HBL-100). Biochem Pharmacol. 1988;37(15):3035–7.CrossRefPubMed
16.
Bruzzone A, Sauliere A, Finana F, Senard JM, Luthy I, Gales C. Dosage-dependent regulation of cell proliferation and adhesion through dual beta2-adrenergic receptor/cAMP signals. FASEB J. 2014;28(3):1342–54.CrossRefPubMed
17.
Cakir Y, Plummer III HK, Tithof PK, Schuller HM. Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol. 2002;21(1):153–7.PubMed
18.
Shi M, Liu D, Duan H, Qian L, Wang L, Niu L, et al. The beta2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat. 2011;125(2):351–62.CrossRefPubMed
19.
Re G, Badino P, Girardi C, Di Carlo F. Effects of a beta 2-agonist (clenbuterol) on cultured human (CG-5) breast cancer cells. Pharmacol Res. 1992;26(4):377–84.CrossRefPubMed
20.
Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010;70(18):7042–52.CrossRefPubMedPubMedCentral
21.
Gargiulo L, Copsel S, Rivero EM, Gales C, Senard JM, Luthy IA, et al. Differential beta(2)-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines. Oncotarget. 2014;5(20):10058–69.CrossRefPubMedPubMedCentral
22.
Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973;51(5):1409–16.CrossRefPubMed
23.
Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5–23.CrossRefPubMed
24.
Soule HD, Maloney TM, Wolman SR, Peterson Jr WD, Brenz R, McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990;50(18):6075–86.PubMed
25.
Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, et al. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat. 2013;142(2):237–55.CrossRefPubMedPubMedCentral
26.
Vazquez SM, Mladovan AG, Perez C, Bruzzone A, Baldi A, Luthy IA. Human breast cell lines exhibit functional alpha2-adrenoceptors. Cancer Chemother Pharmacol. 2006;58(1):50–61.CrossRefPubMed
27.
Tubio MR, Fernandez N, Fitzsimons CP, Copsel S, Santiago S, Shayo C, et al. Expression of a G protein-coupled receptor (GPCR) leads to attenuation of signaling by other GPCRs: experimental evidence for a spontaneous GPCR constitutive inactive form. J Biol Chem. 2010;285(20):14990–8.CrossRefPubMedPubMedCentral
28.
Lavoie C, Mercier JF, Salahpour A, Umapathy D, Breit A, Villeneuve LR, et al. Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem. 2002;277(38):35402–10.CrossRefPubMed
29.
Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods. 2003;30(3):256–68.CrossRefPubMed
30.
Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery Jr CA, et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 1995;9(18):2266–78.CrossRefPubMed
31.
Sahores A, Luque GM, Wargon V, May M, Molinolo A, Becu-Villalobos D, et al. Novel, low cost, highly effective, handmade steroid pellets for experimental studies. PLoS One. 2013;8(5):e64049.CrossRefPubMedPubMedCentral
32.
Vanzulli S, Efeyan A, Benavides F, Helguero LA, Peters G, Shen J, et al. p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis. 2002;23(5):749–58.CrossRefPubMed
33.
34.
Gouon-Evans V, Pollard JW. Unexpected deposition of brown fat in mammary gland during postnatal development. Mol Endocrinol. 2002;16(11):2618–27.CrossRefPubMed
35.
Kouros-Mehr H, Werb Z. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn. 2006;235(12):3404–12.CrossRefPubMedPubMedCentral
36.
Wargon V, Riggio M, Giulianelli S, Sequeira GR, Rojas P, May M, et al. Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters. Int J Cancer. 2015;136(11):2680–92.CrossRefPubMed
37.
Silberstein GB, Strickland P, Trumpbour V, Coleman S, Daniel CW. In vivo, cAMP stimulates growth and morphogenesis of mouse mammary ducts. Proc Natl Acad Sci U S A. 1984;81(15):4950–4.CrossRefPubMedPubMedCentral
38.
Liu S, Lin YC. Transformation of MCF-10A human breast epithelial cells by zeranol and estradiol-17beta. Breast J. 2004;10(6):514–21.CrossRefPubMed
39.
40.
Draoui A, Vandewalle B, Hornez L, Revillion F, Lefebvre J. Beta-adrenergic receptors in human breast cancer: identification, characterization and correlation with progesterone and estradiol receptors. Anticancer Res. 1991;11(2):677–80.PubMed
41.
Powe DG, Entschladen F. Targeted therapies: using beta-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol. 2011;8(9):511–2.CrossRefPubMed
42.
Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628–38.CrossRefPubMedPubMedCentral
43.
Monami M, Filippi L, Ungar A, Sgrilli F, Antenore A, Dicembrini I, et al. Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Curr Med Res Opin. 2013;29(4):369–78.CrossRefPubMed
44.
Raimondi S, Botteri E, Munzone E, Cipolla C, Rotmensz N, DeCensi A, et al. Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis. Int J Cancer. 2016;139(1):212–9.CrossRefPubMed
45.
van der Westhuizen ET, Breton B, Christopoulos A, Bouvier M. Quantification of ligand bias for clinically relevant beta2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol. 2014;85(3):492–509.CrossRefPubMed
46.
Vrydag W, Michel MC. Tools to study beta3-adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol. 2007;374(5–6):385–98.CrossRef
47.
Vandewalle B, Revillion F, Lefebvre J. Functional beta-adrenergic receptors in breast cancer cells. J Cancer ResClinOncol. 1990;116(3):303–6.
48.
Badino GR, Novelli A, Girardi C, Di Carlo F. Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res. 1996;33(4–5):255–60.PubMed
49.
Shamir ER, Ewald AJ. Three-dimensional organotypic culture: experimental models of mammalian biology and disease. Nat Rev Mol Cell Biol. 2014;15(10):647–64.CrossRefPubMedPubMedCentral
50.
Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 2005;5(9):675–88.CrossRefPubMed
51.
Nedvetsky PI, Kwon SH, Debnath J, Mostov KE. Cyclic AMP regulates formation of mammary epithelial acini in vitro. Mol Biol Cell. 2012;23(15):2973–81.CrossRefPubMedPubMedCentral
52.
Russo J, Hu YF, Yang X, Russo IH. Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr. 2000;27:17–37.CrossRef
53.
Rajkumar L, Guzman RC, Yang J, Thordarson G, Talamantes F, Nandi S. Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis. Proc Natl Acad Sci U S A. 2001;98(20):11755–9.CrossRefPubMedPubMedCentral
54.
Hermes GL, Delgado B, Tretiakova M, Cavigelli SA, Krausz T, Conzen SD, et al. Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc Natl Acad Sci U S A. 2009;106(52):22393–8.CrossRefPubMedPubMedCentral
55.
Mallepell S, Krust A, Chambon P, Brisken C. Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A. 2006;103(7):2196–201.CrossRefPubMedPubMedCentral
56.
Brisken C, Park S, Vass T, Lydon JP, O’Malley BW, Weinberg RA. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci U S A. 1998;95(9):5076–81.CrossRefPubMedPubMedCentral
57.
Hurley MM, Tetradis S, Huang YF, Hock J, Kream BE, Raisz LG, et al. Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. J Bone Miner Res. 1999;14(5):776–83.CrossRefPubMed
58.
Rajakumar RA, Quinn CO. Parathyroid hormone induction of rat interstitial collagenase mRNA in osteosarcoma cells is mediated through an AP-1-binding site. Mol Endocrinol. 1996;10(7):867–78.PubMed
59.
Marchese S, Silva E. Disruption of 3D MCF-12A breast cell cultures by estrogens--an in vitro model for ER-mediated changes indicative of hormonal carcinogenesis. PLoS One. 2012;7(10):e45767.CrossRefPubMedPubMedCentral
60.
Yu M, Lin G, Arshadi N, Kalatskaya I, Xue B, Haider S, et al. Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation. Mol Cell Biol. 2012;32(19):3913–24.CrossRefPubMedPubMedCentral
61.
62.
Metadata
Title
A Novel Effect of β-Adrenergic Receptor on Mammary Branching Morphogenesis and its Possible Implications in Breast Cancer
Authors
Lucía Gargiulo
María May
Ezequiel M. Rivero
Sabrina Copsel
Caroline Lamb
John Lydon
Carlos Davio
Claudia Lanari
Isabel A. Lüthy
Ariana Bruzzone
Publication date
01-03-2017
Publisher
Springer US
Published in
Journal of Mammary Gland Biology and Neoplasia / Issue 1/2017
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI
https://doi.org/10.1007/s10911-017-9371-1

Other articles of this Issue 1/2017

Journal of Mammary Gland Biology and Neoplasia 1/2017 Go to the issue

OriginalPaper

Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model

OriginalPaper

Variation of Human Milk Glucocorticoids over 24 hour Period

OriginalPaper

Role of Prolactin in Promotion of Immune Cell Migration into the Mammary Gland

OriginalPaper

Mouse Models of Breast Cancer Share Amplification and Deletion Events with Human Breast Cancer

OriginalPaper

Accurate Control of 17β-Estradiol Long-Term Release Increases Reliability and Reproducibility of Preclinical Animal Studies

OriginalPaper

Reelin Deficiency Delays Mammary Tumor Growth and Metastatic Progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits